Results 1 to 10 of about 922,189 (320)

In situ click chemistry generation of cyclooxygenase-2 inhibitors [PDF]

open access: yesNature Communications, 2017
Traditional inflammation and pain relief drugs target both cyclooxygenase 1 and 2 (COX-1 and COX-2), causing severe side effects. Here, the authors use in situ click chemistry to develop COX-2 specific inhibitors with high in vivo anti-inflammatory ...
Atul Bhardwaj   +3 more
doaj   +3 more sources

Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach [PDF]

open access: yesPharmaceuticals, 2020
The cyclooxygenase-2 receptor is a therapeutic target for planning potential drugs with anti-inflammatory activity. The selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib was selected as a pivot molecule to perform virtual ligand-based screening from
Rozires P. Leão   +9 more
doaj   +3 more sources

Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors [PDF]

open access: yesMolecules, 2019
Quinones and nitrogen heterocyclic moieties have been recognized as important pharmacophores in the development of antitumor agents. This study aimed to establish whether there was any correlation between the in silico predicted parameters and the in ...
Aurora Molinari   +7 more
doaj   +5 more sources

Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials. [PDF]

open access: yesPLoS ONE, 2016
BackgroundEvidence on the benefits of combining cyclooxygenase-2 inhibitor (COX-2) in treating non-small cell lung cancer (NSCLC) is still controversial.
Yuan Yuan Zhou   +3 more
doaj   +3 more sources

Synthesis and Biological Evaluation of Gentiopicroside Derivatives as Novel Cyclooxygenase-2 Inhibitors with Anti-Inflammatory Activity [PDF]

open access: yesDrug Design, Development and Therapy, 2023
Guojin Ren,1,* Qili Zhang,1,2,* Pengfei Xia,1– 4 Jie Wang,1 Pengxia Fang,1 Xiaojie Jin,1 Xuejing Peng,1– 4 Yanli Xu,1,5 Jian Zhang,1– 4 Lei Zhao1– 5 1Gansu University of Chinese Medicine, Lanzhou, 730000, People’s Republic of China; 2Northwest ...
Ren G   +9 more
doaj   +2 more sources

Cyclooxygenase-2 inhibitors: promise or peril? [PDF]

open access: yesMediators of Inflammation, 2002
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized ...
Laurel J. Mengle-Gaw   +1 more
doaj   +4 more sources

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management

open access: yesJournal of Neuroinflammation, 2019
Epilepsy, a common multifactorial neurological disease, affects about 69 million people worldwide constituting nearly 1% of the world population.
Chitra Rawat   +3 more
doaj   +2 more sources

Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. [PDF]

open access: yesDrugs Aging, 2019
ObjectiveOur aim was to assess the safety of cyclooxygenase-2 (COX-2) inhibitors in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials.MethodsA comprehensive literature search was ...
Curtis E   +13 more
europepmc   +2 more sources

Safety and potential efficacy of cyclooxygenase‐2 inhibitors in coronavirus disease 2019 [PDF]

open access: yesClinical & Translational Immunology, 2020
Objectives While the safety of non‐steroidal anti‐inflammatory drugs in COVID‐19 has been questioned, they may be beneficial given the hyper‐inflammatory immune response associated with severe disease. We aimed to assess the safety and potential efficacy
Sean Wei Xiang Ong   +8 more
doaj   +2 more sources

Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders

open access: yesFrontiers in Psychiatry, 2019
Neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden.
Rickinder Sethi   +14 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy